Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
NCT07281014Phase 4Active, not recruiting
- Sponsor
- Yale University
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone, aldosterone in heart failure (HF), sponsored by Yale University. Started Jan 2026; status: active, not recruiting.
02
Drugs
spironolactonealdosterone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07281014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281014.